探索菲律宾开发COVID-19疫苗的基本需求。

Dalmacito A Cordero
{"title":"探索菲律宾开发COVID-19疫苗的基本需求。","authors":"Dalmacito A Cordero","doi":"10.7774/cevr.2023.12.3.260","DOIUrl":null,"url":null,"abstract":"I am interested in the recent article published in this journal regarding the experience of developing coronavirus disease 2019 (COVID-19) vaccines in Iran. The authors appropriately presented the necessity of widespread public vaccination during health crises. They emphasized that vaccine development was a complex process that requires firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies [1]. In this regard, the Philippines can learn from the vaccine development experience of Iran since both are categorized as developing countries. At the same time, the government has finally started planning to establish its vaccine development plan to address the shortage/unavailability of vaccines and vaccine hesitancy among local citizens. In the current data reported to the World Health Organization, there have been 4,076,237 confirmed cases of COVID-19, with 66,108 deaths from 3 January 2020 to 28 February 2023. These alarming figures could have been prevented, especially the number of deaths if the first dose of vaccines had arrived earlier or had been available during the first months of the pandemic. Unfortunately, the first tranche of CoronaVac vaccine doses from China’s Sinovac Biotech arrived after almost a year, in February 2021, making it one of the last countries in Southeast Asia to start vaccinating its residents [2]. In the same way, even if vaccines were already available, many locals are hesitant to get inoculated due to several reasons and myths, such as the life span of those who are vaccinated is shortened; vaccines are viewed as unnecessary and insufficient to prevent disease; the young ones do not need the vaccines, but only those at high risk, especially the elderly and persons with comorbidities; the vaccine can give you COVID-19 since it contains the virus; the vaccine can cause infertility among women, persons with an allergy should not get the vaccine, and other participants cited that other countries did not recognize a specific brand. Thus, they are ineffective [3,4]. If vaccines are locally manufactured and explained well in Filipino culture and tradition, then there is the possibility of more acceptance and addressing the hesitancy. Just like in Iran, where the development of the COVID-19 vaccine was accelerated due to simultaneous cooperation and competition of various research centers/companies, and there was enough government financial/regulatory support [1], these same factors must also be given priority in the Philippines. It is good that several research centers have started to work hard for its cause, like the Philippine Council for Health Research and Development, the National Institutes of Health, and the Re© Korean Vaccine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. K O R E A N V A C C I N E S O C I E T Y","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"12 3","pages":"260-261"},"PeriodicalIF":2.1000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/31/cevr-12-260.PMC10435769.pdf","citationCount":"0","resultStr":"{\"title\":\"Exploring the essential need for developing COVID-19 vaccines in the Philippines.\",\"authors\":\"Dalmacito A Cordero\",\"doi\":\"10.7774/cevr.2023.12.3.260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"I am interested in the recent article published in this journal regarding the experience of developing coronavirus disease 2019 (COVID-19) vaccines in Iran. The authors appropriately presented the necessity of widespread public vaccination during health crises. They emphasized that vaccine development was a complex process that requires firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies [1]. In this regard, the Philippines can learn from the vaccine development experience of Iran since both are categorized as developing countries. At the same time, the government has finally started planning to establish its vaccine development plan to address the shortage/unavailability of vaccines and vaccine hesitancy among local citizens. In the current data reported to the World Health Organization, there have been 4,076,237 confirmed cases of COVID-19, with 66,108 deaths from 3 January 2020 to 28 February 2023. These alarming figures could have been prevented, especially the number of deaths if the first dose of vaccines had arrived earlier or had been available during the first months of the pandemic. Unfortunately, the first tranche of CoronaVac vaccine doses from China’s Sinovac Biotech arrived after almost a year, in February 2021, making it one of the last countries in Southeast Asia to start vaccinating its residents [2]. In the same way, even if vaccines were already available, many locals are hesitant to get inoculated due to several reasons and myths, such as the life span of those who are vaccinated is shortened; vaccines are viewed as unnecessary and insufficient to prevent disease; the young ones do not need the vaccines, but only those at high risk, especially the elderly and persons with comorbidities; the vaccine can give you COVID-19 since it contains the virus; the vaccine can cause infertility among women, persons with an allergy should not get the vaccine, and other participants cited that other countries did not recognize a specific brand. Thus, they are ineffective [3,4]. If vaccines are locally manufactured and explained well in Filipino culture and tradition, then there is the possibility of more acceptance and addressing the hesitancy. Just like in Iran, where the development of the COVID-19 vaccine was accelerated due to simultaneous cooperation and competition of various research centers/companies, and there was enough government financial/regulatory support [1], these same factors must also be given priority in the Philippines. It is good that several research centers have started to work hard for its cause, like the Philippine Council for Health Research and Development, the National Institutes of Health, and the Re© Korean Vaccine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. K O R E A N V A C C I N E S O C I E T Y\",\"PeriodicalId\":51768,\"journal\":{\"name\":\"Clinical and Experimental Vaccine Research\",\"volume\":\"12 3\",\"pages\":\"260-261\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/31/cevr-12-260.PMC10435769.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Vaccine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7774/cevr.2023.12.3.260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2023.12.3.260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Exploring the essential need for developing COVID-19 vaccines in the Philippines.
I am interested in the recent article published in this journal regarding the experience of developing coronavirus disease 2019 (COVID-19) vaccines in Iran. The authors appropriately presented the necessity of widespread public vaccination during health crises. They emphasized that vaccine development was a complex process that requires firm-level capabilities, various infrastructures, long-term planning, and stable and efficient policies [1]. In this regard, the Philippines can learn from the vaccine development experience of Iran since both are categorized as developing countries. At the same time, the government has finally started planning to establish its vaccine development plan to address the shortage/unavailability of vaccines and vaccine hesitancy among local citizens. In the current data reported to the World Health Organization, there have been 4,076,237 confirmed cases of COVID-19, with 66,108 deaths from 3 January 2020 to 28 February 2023. These alarming figures could have been prevented, especially the number of deaths if the first dose of vaccines had arrived earlier or had been available during the first months of the pandemic. Unfortunately, the first tranche of CoronaVac vaccine doses from China’s Sinovac Biotech arrived after almost a year, in February 2021, making it one of the last countries in Southeast Asia to start vaccinating its residents [2]. In the same way, even if vaccines were already available, many locals are hesitant to get inoculated due to several reasons and myths, such as the life span of those who are vaccinated is shortened; vaccines are viewed as unnecessary and insufficient to prevent disease; the young ones do not need the vaccines, but only those at high risk, especially the elderly and persons with comorbidities; the vaccine can give you COVID-19 since it contains the virus; the vaccine can cause infertility among women, persons with an allergy should not get the vaccine, and other participants cited that other countries did not recognize a specific brand. Thus, they are ineffective [3,4]. If vaccines are locally manufactured and explained well in Filipino culture and tradition, then there is the possibility of more acceptance and addressing the hesitancy. Just like in Iran, where the development of the COVID-19 vaccine was accelerated due to simultaneous cooperation and competition of various research centers/companies, and there was enough government financial/regulatory support [1], these same factors must also be given priority in the Philippines. It is good that several research centers have started to work hard for its cause, like the Philippine Council for Health Research and Development, the National Institutes of Health, and the Re© Korean Vaccine Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. K O R E A N V A C C I N E S O C I E T Y
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
期刊最新文献
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients. Root causes of low influenza vaccination coverage rates among nurses working in a tertiary care university hospital in Turkey: result of a study using nominal group technique. Safety and immunogenicity of an inactivated vero cell-based rabies vaccine (Rabivax-S) in pre-exposure prophylaxis schedule in Vietnam. Vaccination status of elite athletes in the German Armed Forces: a retrospective descriptive overview. A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1